HIGHLIGHTS
- who: Lawsuit et al. from the Hunan University, China have published the research work: The patent dispute over the breakthrough mRNA technology, in the Journal: (JOURNAL) of 10/01/2022
SUMMARY
Frontiersin.org 10.3389/fbioe.2022.1049873 already known to be highly expressed. The latter could be understood if Pfizer/BioNTech demonstrates that incorporating native nucleotides in its mRNA_vaccine leads to the same results as using m1ψ, regardless of which 5`-UTR region is used. Critical comparison of the COVID-19 mRNA_vaccines made by Moderna and Pfizer/BioNTech To analyze the basis . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.